Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA:688796)
China flag China · Delayed Price · Currency is CNY
77.00
-0.50 (-0.65%)
At close: Mar 9, 2026

SHA:688796 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020
Cash & Equivalents
-403.85417.66626.62466.45
Upgrade
Short-Term Investments
-7.257.899.15106.98
Upgrade
Trading Asset Securities
--8.498.2-
Upgrade
Cash & Short-Term Investments
-411.1434.04643.97573.42
Upgrade
Cash Growth
--5.29%-32.60%12.30%-40.11%
Upgrade
Accounts Receivable
-229.61142.38107.68103.09
Upgrade
Other Receivables
-11.046.044.1714.96
Upgrade
Receivables
-240.65148.43111.85118.05
Upgrade
Inventory
-5.399.923.7321.65
Upgrade
Other Current Assets
-159.41130.69139.74161.11
Upgrade
Total Current Assets
-816.54723.05919.3874.24
Upgrade
Property, Plant & Equipment
-1,3491,4511,5991,391
Upgrade
Long-Term Investments
-222.61241.24250.819.69
Upgrade
Other Intangible Assets
-20.6728.1330.656.06
Upgrade
Long-Term Deferred Tax Assets
-0.96---
Upgrade
Other Long-Term Assets
-5.066.16-21.86
Upgrade
Total Assets
-2,4152,4492,8002,303
Upgrade
Accounts Payable
-115.48175.23146.19102.44
Upgrade
Accrued Expenses
-30.1827.8951.6253.66
Upgrade
Current Portion of Long-Term Debt
-208.14176.84126.67-
Upgrade
Current Portion of Leases
-17.8626.3644.9426.9
Upgrade
Current Income Taxes Payable
-12.814.514.25.02
Upgrade
Current Unearned Revenue
-102.1969.2256.3861.58
Upgrade
Other Current Liabilities
-48.2697.56176.06196.96
Upgrade
Total Current Liabilities
-534.91577.62606.05446.56
Upgrade
Long-Term Debt
-193.84173.9152.17-
Upgrade
Long-Term Leases
-150.45167.01191.5162.9
Upgrade
Long-Term Unearned Revenue
-84.987.0789.9392.8
Upgrade
Long-Term Deferred Tax Liabilities
--1.9--
Upgrade
Other Long-Term Liabilities
-612.62651.48709.36448.55
Upgrade
Total Liabilities
-1,5771,6591,6491,051
Upgrade
Common Stock
-399.4399.4399.4374.93
Upgrade
Additional Paid-In Capital
-1,9921,9921,9921,516
Upgrade
Retained Earnings
--1,754-1,787-1,404-802.32
Upgrade
Treasury Stock
--32.77-27.18-18.99-
Upgrade
Comprehensive Income & Other
-229.3209.09178.32159.03
Upgrade
Total Common Equity
-834.06785.891,1461,247
Upgrade
Minority Interest
-4.554.554.554.76
Upgrade
Shareholders' Equity
-838.6790.441,1511,252
Upgrade
Total Liabilities & Equity
-2,4152,4492,8002,303
Upgrade
Total Debt
-570.28544.11415.2889.8
Upgrade
Net Cash (Debt)
--159.18-110.07228.69483.62
Upgrade
Net Cash Growth
----52.71%-44.82%
Upgrade
Net Cash Per Share
--0.40-0.280.601.33
Upgrade
Filing Date Shares Outstanding
409.32399.4399.4399.4396.69
Upgrade
Total Common Shares Outstanding
409.32399.4399.4399.4374.93
Upgrade
Working Capital
-281.62145.43313.25427.68
Upgrade
Book Value Per Share
-2.091.972.873.33
Upgrade
Tangible Book Value
-813.39757.761,1161,241
Upgrade
Tangible Book Value Per Share
-2.041.902.793.31
Upgrade
Machinery
-1,5021,4371,2081,107
Upgrade
Construction In Progress
-1.95.19268.29181.96
Upgrade
Leasehold Improvements
-232.8240.53161.75166.43
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.